Fig. 6
From: Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Spheroid growth (a and b) and spheroid Invasion (c and d) assays of prostate-induced bone metastasis cells treated with vehicle (PBS1x) or zol 10 µM for 7 days in 1% serum conditions. Representative brightfield images of spheroids growth (a) and invasion (c) of prostate-induced bone metastasis cells from vehicle or zol-treated conditions. Histograms for spheroids growth (b) and invasion (d) showing the mean ± SD of three independent experiments, p < 0.05. Each condition (drug-treated cells or vehicle-treated cells) on each day was normalized to day 0 and then all normalized conditions were again normalized to vehicle (PBS1x)